<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378883</url>
  </required_header>
  <id_info>
    <org_study_id>NV-APL001</org_study_id>
    <nct_id>NCT02378883</nct_id>
  </id_info>
  <brief_title>Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study</brief_title>
  <official_title>Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Micro
      Catheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous
      malformation (AVM) embolization procedures.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of catheter-related adverse events per Subject</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Secondary Endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of catheter tip detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Secondary Endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of migration of the retained catheter tip post embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Secondary Endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of procedure-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Secondary Endpoints</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of catheter/tip leakage from detachment zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-Term Secondary Endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-Term Secondary Endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of migration of the retained catheter tip post embolization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>AVM treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Apollo™ Onyx™ Delivery Micro Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apollo™ Onyx™ Delivery Micro Catheter</intervention_name>
    <arm_group_label>AVM treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The Subject or Subject's legally authorized representative has signed and dated an
             informed consent form.

          -  The Subject has a confirmed diagnosis of a brain AVM.

          -  The Subject is clinically and neurologically stable for a minimum of 48 hours prior to
             embolization.

          -  The Subject has a life expectancy of at least 1 year.

          -  The Subject agrees to and is capable of completing all study-required procedures.

        Exclusion Criteria:

          -  Current participation in another investigational drug or device study that evaluates
             treatments for brain AVMs or other cerebrovascular disease.

          -  The Subject has a bleeding disorder.

          -  The Subject is not a candidate for the use of vasodilators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radiology Imaging Associates, P.C.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham's &amp; Women Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apollo</keyword>
  <keyword>Onyx</keyword>
  <keyword>arteriovenous malformation</keyword>
  <keyword>AVM</keyword>
  <keyword>Onyx™ Liquid Embolic System</keyword>
  <keyword>Apollo™ Onyx™ Delivery Micro Catheter</keyword>
  <keyword>Brain Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

